PHC HoldingsPHC Holdings Corporation6523東証プライム電気機器FY ending Mar 2026, consolidated, IFRS
About 37% of PHC Holdings's sales come from Diagnostics and Life Sciences, with Healthcare Solutions and Diabetes Management making up much of the rest.
Out of every ¥100 of sales, about ¥1 is left as operating profit.
Revenue changed -0.7% from the prior year, operating profit -92.2%.
Revenue -0.7% · profit -92.2%, calculated from disclosed figures.
Operating leverage: 129.65× (profit growth ÷ revenue growth)
FY ending Mar 2023 → FY ending Mar 2024
FY ending Mar 2023 → FY ending Mar 2024
For every ¥100 PHC Holdings sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
Revenue by business segment, and the profit each one keeps.
※ Segment figures include inter-segment sales and do not sum to the company total
EDINET (FSA Japan)
有価証券報告書-第13期(2025/04/01-2026/03/31)
EDINET (FSA Japan)
有価証券報告書-第12期(2024/04/01-2025/03/31)
EDINET (FSA Japan)
有価証券報告書-第11期(2023/04/01-2024/03/31)
EDINET (FSA Japan)
有価証券報告書-第10期(2022/04/01-2023/03/31)
EDINET (FSA Japan)
有価証券報告書-第9期(令和3年4月1日-令和4年3月31日)
Extracted from XBRL: 44 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.